Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer
Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer
复制标题
DOI：
10.21873/anticanres.11614
复制
发表时间：
2017-05-01
影响因子：
2
通讯作者：
Baba, Eishi
中科院分区：
文献类型：
--
作者：
Inadomi, Kyoko;Kusaba, Hitoshi;Baba, Eishi
背景：以奥沙利铂为基础的化疗对晚期胃癌（AGC）有显著疗效。然而，奥沙利铂的适当剂量，以及顺铂治疗后给予奥沙利铂的疗效和毒性仍不清楚。患者和方法：共对55例计划接受奥沙利铂化疗的AGC患者进行前瞻性检查。结果：中位年龄为67岁，39例（71%）患者接受奥沙利铂作为一线治疗，16例（29%）患者接受奥沙利铂作为二线治疗。初始剂量分别为130或100mg /m(2)的奥沙利铂给予11名和36名患者。总缓解率（ORR）和中位无进展生存期（mPFS）分别为86%和33%，7.2和7.8个月。与100 mg/m(2)相比，奥沙利铂在130 mg/m(2)时的相对剂量强度明显降低，严重毒性有增加的趋势。共有10名患者（18%）先前接受过以顺铂为基础的治疗。顺铂预处理组的ORR为14%，mPFS为6.1个月。结论：初始剂量为130 mg/m(2)的奥沙利铂可获得良好的疗效，但有增加毒性风险的倾向。顺铂后的后续奥沙利铂治疗显示出适度的疗效，特别是在顺铂不耐受的病例中。
Background: Significant efficacy of oxaliplatin-based chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71%) patients as first-line and in 16 (29%) patients as second-line therapy. An initial dose of 130 or 100 mg/m(2) of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33%, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m(2), the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m(2). A total of 10 patients (18%) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14% and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m(2) resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.